Month: February 2021

Excellent progress on clinical programsUnprecedented partnering deal signed with Pfizer for Lyme disease vaccine candidate VLA15, including $130 million upfront payment as part of over $300 million for upfront and milestone paymentsPositive initial Phase 2 resultsAcceleration of pediatric development announcedAcceleration of chikungunya vaccine candidate VLA1553 into Phase 3Only Phase 3 chikungunya vaccine program to date worldwidePotentially eligible for Priority Review Voucher (PRV)1 – for first company to receive Biologics License Application (BLA) approvalCommercial business adversely affected by pandemic impact on travel industryNew US military / Department of Defense (DoD) contract for IXIARO® worth up to $166 million over three years Valneva contributing to the global effort against the COVID-19 pandemicOnly whole-virus inactivated...

Très bonne avancée des programmes cliniquesPartenariat sans précédent signé avec Pfizer pour le candidat vaccin contre la maladie de Lyme VLA15, dont $130 millions de paiement initial reçus dans le cadre des paiements d’un montant total de plus de $300 millions pouvant être reçus par ValnevaPremiers résultats de Phase 2 positifsAccélération du développement pédiatrique annoncéeAccélération du développement du candidat vaccin contre le chikungunya VLA1553 avec une entrée en Phase 3Seul programme vaccinal contre le chikungunya actuellement en Phase 3 dans le mondePotentiellement éligible à un bon d’évaluation prioritaire (PRV)1 – pour la société recevant la première autorisation de mise sur le marché aux Etats-Unis (BLA)Activité commerciale négativement affectée par l’impact de la pandémie de COVID-19 sur l’industrie du voyageNouveau contract...

Kinepolis limits cash burn in 2020 and maintains a solid financial basis throughout the Covid-19 crisisRegulatory release25 February 2021, 7 a.m.After a promising start of the year 2020 for Kinepolis, with a 12.0% increase in visitor numbers up to 12 March, the cinema industry was badly hit by the Covid-19 pandemic, with long periods of cinema closures and restrictive measures as well as repeated postponements of blockbuster movie releases. As such, Kinepolis welcomed 12.1 million visitors in 2020, compared to initial expectations of more than 45 million visitors. Thanks to strong cost control and various measures that were taken, the EBITDA loss, adjusted for leases (EBITDAL), has been limited to € -14.0 million.Kinepolis entered the crisis with a conservative debt ratio and a significant liquidity reserve, reinforced by the additional...

Kinepolis a réussi à limiter sa consommation de trésorerie en 2020 et maintient une base financière solide durant la crise de la Covid-19Information réglementée25 février 2021, 7h00Après un début d’année 2020 prometteur pour Kinepolis, avec une augmentation de 12,0 % des visiteurs jusqu’au 12 mars, l’industrie du cinéma a été durement touchée par la pandémie de Covid-19, ce qui a entraîné de longues périodes de fermeture des cinémas, des mesures restrictives et des reports répétés de sorties de superproductions. Kinepolis a ainsi accueilli 12,1 millions de visiteurs en 2020, alors que l’on s’attendait initialement à plus de 45 millions de visiteurs. Grâce à un contrôle rigoureux des coûts et aux mesures prises, la perte d’EBITDA, ajustée pour les loyers (EBITDAL), a été limitée à -14,0 millions €.Kinepolis est entré dans la crise avec...

Kinepolis beperkt cash burn in 2020 en behoudt een solide financiële basis doorheen de Covid-19 crisisGereglementeerd bericht25 februari 2021, 07u00Na een veelbelovende start van het jaar 2020 voor Kinepolis, met een bezoekersstijging van 12,0% tot en met 12 maart, werd de bioscoopindustrie hard getroffen door de Covid-19 pandemie, met lange periodes van sluiting van bioscopen, beperkende maatregelen en een herhaaldelijk uitstel van blockbuster filmreleases tot gevolg.  Zo ontving Kinepolis in 2020 slechts 12,1 miljoen bezoekers, versus een initiële verwachting van meer dan 45 miljoen bezoekers. Dankzij de sterke kostenbeheersing en genomen maatregelen kon het EBITDA-verlies, aangepast voor huur (EBITDAL), worden beperkt tot € -14,0 miljoen.Kinepolis is de crisis ingegaan met een conservatieve schuldgraad en een aanzienlijke liquiditeitsreserve,...

In its 30th anniversary year, SalMar is strengthening its substantial endeavours in the field of offshore fish farming, and through this way contribute to solving important environmental and area challenges the aquaculture industry faces. To strengthen the team at SalMar Ocean, Group CFO & COO Trine Sæther Romuld, in consultation with SalMar’s CEO and board of directors, has announced her decision to accept the role of CFO & Director of Strategy at SalMar Ocean, when a new Group CFO in SalMar is recruited to SalMar. The recruitment process for a new group CFO is already underway and the plan is for her to take up her new post on 1 September 2021.“SalMar’s focus on the open ocean marked the start of a new era in the seafood industry. Offshore fish farming opens vast new areas for sustainable food production and helps to secure...

SalMar fyller 30 år og styrker i jubileumsåret planene for sin ambisiøse satsing på havbasert produksjon av laks, og på den måten bidra til å løse viktige miljø- og arealutfordringer som havbruksnæringen står overfor. For å styrke teamet i SalMar Ocean har CFO & COO Trine Sæther Romuld – i samråd med CEO og styret i SalMar ASA – meddelt at hun påtar seg rollen som CFO & strategiansvarlig i SalMar Ocean og vil derfor, når ny CFO er rekruttert til SalMar, gå over til ny stilling i SalMar Ocean. Rekruttering av ny CFO i SalMar er igangsatt og det planlegges at Romuld gjennomfører skifte til SalMar Ocean 1. september 2021.– SalMars satsing på hav markerte starten på en ny æra innen sjømatnæringen. Havbasert oppdrett åpner for bærekraftig matproduksjon i store nye områder og bidrar til å sikre verdens matforsyning også...

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 25, 2021 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced the pricing of its previously announced underwritten registered public offering of 2,795,000 shares of its common stock at a public offering price of US$21.50 per share. As part of the offering, AVITA Medical granted the underwriters a 30-day option to purchase at the public offering price up to an additional 419,250 shares of its common stock on the same terms and conditions. All of the shares of common stock to be sold in the offering are being offered by AVITA Medical. AVITA Medical expects to close the...

Highlights in the fourth quarter:Operational EBIT of NOK 413.8 million, EBIT per kg of NOK 9.50. Fish Farming Central Norway and Fish Farming Northern Norway post satisfactory results based on a good biological and operational performance. Low salmon prices and a challenging market affected the results for Sales & Processing. Positive cost development for Icelandic Salmon, with a significantly lower production costs for the fish harvested. However, a challenging market with low salmon prices resulted in an operating loss. Guiding for 2021 maintained at 163,000 tonnes in Norway and 14,000 tonnes in Iceland. The board of directors recommends a dividend of NOK 20 per share for the 2020 financial year. Strengthens strategic focus on offshore fish farming for sustainable growth on the salmon’s terms.             Satisfactory result despite...

Høydepunkter for fjerde kvartal:Operasjonelt driftsresultat (EBIT) på 413,8 millioner kroner, med EBIT per kilo på 9,50 kroner. Segment Midt-Norge og Nord-Norge leverer tilfredsstillende resultater basert på gode biologiske og operasjonelle prestasjoner. Lavere laksepriser og et krevende marked påvirker resultatet fra salg og prosessering. Virksomheten på Island har positiv kostnadsutvikling med betydelig lavere uttakskost, med får et negativt resultat som følge av et krevende marked med lave laksepriser. SalMar opprettholder et forventet slaktevolum for 2021 på 163 000 tonn for Norge og 14 000 tonn på Island. Styret innstiller på et utbytte for 2020 på 20 kroner per aksje. Forsterker satsingen på havbasert oppdrett for å sikre bærekraftig vekst på laksen sine betingelser.Tilfredsstillende resultater i til tross for et krevende markedSalMar...